NCT00052052View on ClinicalTrials.gov

An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

September 30, 2004

Conditions
Lung DiseasePulmonary Fibrosis
Interventions
DRUG

interferon-gamma 1b

200 mcg, SQ, 3x per week

Trial Locations (1)

98195

University of Washington Medical Center, Seattle

Sponsors

Lead Sponsor

InterMune
All Listed Sponsors
lead

InterMune

INDUSTRY

NCT00052052 - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter